GE HealthCare to buy Sofie Biosciences for $945 million to strengthen radiopharma business
GEHC•GE HealthCare said it would buy privately held Sofie Biosciences for $945 million in cash. The deal would give GE HealthCare U.S. rights to experimental PET imaging agent FAPI-74.
1. Cash acquisition
GE HealthCare said it would buy Sofie Biosciences for $945 million in cash, strengthening its ability to manufacture and distribute PET imaging drugs. The transaction is expected to close in the first half of 2027.
2. FAPI-74 rights
The acquisition would give GE HealthCare U.S. rights to FAPI-74, an experimental PET imaging agent in late-stage testing that could be used to detect several types of cancer; GE HealthCare already owns rights outside the United States. Sofie develops products including radioisotopes used in PET scans and operates facilities that make and distribute them for hospitals and imaging centers. It will continue manufacturing products for existing customers, including other radiopharma companies, after the deal closes.
